Pharma IP teams are used to thinking in timelines: filing windows, priority dates, prosecution milestones, and—eventually—patent expiry. But in Russia, the “clock” isn’t just about when a patent ends. It’s also about how long you can extend it, under w…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Most pharma patent strategies are built for one moment: filing.
But the market doesn’t reward filings—it rewards enforceable rights.
In today’s environment…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Generic launches don’t “happen.” They arrive—on a schedule you can model.
Most teams treat generic entry like a calendar event: wait for the FDA to publish, monitor label changes, and react when the first ANDA approval hits. By then, the window for pri…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

The “patent cliff” isn’t just a pharma problem—it’s a talent problem.
Most people talk about the patent cliff as a revenue event: when exclusivity ends, generics rush in, margins compress, and pipelines get pressure-tested overnight. But there’s anothe…

Stop Overstocking. Start Seeing Patent Risk.
Branded drug inventory risk isn’t just a supply-chain problem—it’s a patent problem.
Wholesalers have long managed demand volatility, forecasting errors, and contract constraints. But in branded pharmaceut…

Big Pharma’s “patent cliff” isn’t just a revenue story—it’s a hiring story.
When investors talk about patent cliffs, they usually focus on one thing: the moment exclusivity ends and generic competition arrives. But there’s a quieter signal hiding in pl…

Biosimilar sourcing is no longer a procurement exercise—it’s a patent strategy problem.
If you’re planning a switch from an originator to a biosimilar, the hard part isn’t finding a supplier. The hard part is timing.
Because in biosimilars, “availabili…